Eliem Therapeutics Return on Tangible Equity 2021-2024 | CLYM
Current and historical return on tangible equity values for Eliem Therapeutics (CLYM) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Eliem Therapeutics Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.07B |
$0.22B |
-47.62% |
| 2024-03-31 |
$-0.02B |
$0.11B |
-13.73% |
| 2023-12-31 |
$-0.04B |
$0.11B |
-31.25% |
| 2023-09-30 |
$-0.04B |
$0.11B |
-33.26% |
| 2023-06-30 |
$-0.05B |
$0.11B |
-36.51% |
| 2023-03-31 |
$-0.06B |
$0.12B |
-42.15% |
| 2022-12-31 |
$-0.05B |
$0.13B |
-32.86% |
| 2022-09-30 |
$-0.05B |
$0.13B |
-32.78% |
| 2022-06-30 |
$-0.05B |
$0.14B |
-31.20% |
| 2022-03-31 |
$-0.05B |
$0.16B |
-41.07% |
| 2021-12-31 |
$-0.05B |
$0.17B |
-72.35% |
| 2021-06-30 |
$-0.03B |
$-0.05B |
266.67% |
| 2021-03-31 |
$-0.03B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
